gdc

Multiple Myeloma

Welcome to the Multiple Myeloma Resource Navigator for Patients
Multiple Myeloma
This publication was created together with leading patient advocates who shared their experiences and insights, in the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These patient organizations provide education and support to promote your health and well-being, and help with practical matters, logistics, and financial and legal concerns.
Surviving Multiple Myeloma for 29 Years
Patient StoriesMultiple Myeloma
James D. Bond describes his crucial experience in a clinical trial and thanks the devoted care of his wife Kathleen and the medical team for his continued success in battling this deadly blood cancer.
Multiple Myeloma Resource Navigator for Patients
Multiple Myeloma
This special issue was developed together with leading patient advocates, who shared their experiences and insight, with the hope that it will help you connect with patient organizations and resources as you and your care partners navigate through your diagnosis and treatment. These organizations provide education and support for your health and well-being, as well as help with practical matters, logistics, and financial and legal concerns.
Darzalex Faspro Receives New FDA Indication, in Combination with Pomalyst and Dexamethasone, for the Treatment of Patients with Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
In July 2021, the FDA approved a new indication for Darzalex Faspro (daratumumab and hyaluronidase-fihj), for use in combination with Pomalyst (pomalidomide) and dexamethasone, for adults with multiple myeloma who have received at least 1 previous line of therapy.
Sarclisa Now Approved for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
In March 2021, the FDA approved a new indication for Sarclisa (isatuximab-irfc), in combination with Kyprolis and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma.
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
Page 1 of 13
Results 1 - 10 of 123

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest